GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?

The FDA panel discussed Grail's (GRAL) blood test for early cancer detection, Galleri. The stock was halted during the meeting, which is a step toward FDA approval. The test aims to screen asymptomatic people, potentially improving treatment outcomes.

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

GRAIL (GRAL) rose 33.7% to $107.97 after FDA staff raised no major concerns about its Galleri cancer test. The FDA panel will vote on approval for adults 50+. Galleri detected 35% of cancers in PATHFINDER 2 and 31.6% in NHS-Galleri. The test's specificity was above 99.7%. GRAL reported $42.6M in Q2 test revenue and a net loss of $110.2M.

GRAIL, Inc. (GRAL) shares rose 34.7% to $108.78 ahead of an FDA advisory-panel review of its Galleri blood test. The stock now exceeds all analyst targets, with volume reaching 3.3 times its 20-session average. GRAIL reported a Q2 loss of $110.2 million but maintained focus on clinical and commercial priorities. The FDA panel will assess Galleri's benefit-risk profile for adults aged 50 and above.

Grail's stock rose 34.7% after FDA staff reviewers found no major concerns with its Galleri multi-cancer detection test. The FDA's advisory committee will review the test on Wednesday. UBS and RBC initiated coverage with Buy ratings, citing strong clinical data. The Nasdaq and S&P 500 also gained, supporting the rally. Grail's shares reached $108.77, nearing their 52-week high of $118.84.

Grail Inc (GRAL) shares rose 35% after FDA reviewers found no major issues with its Galleri multi-cancer blood test. The test, designed to detect over 50 cancers, will be reviewed by an advisory committee on September 23. The FDA seeks input on the test's benefits and risks.